Media Room Menu
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jun 2, 2022Sanofi will receive an upfront payment of $900 million, and an 11% royalty on worldwide net sales of Libtayo
-
Jun 1, 2022Efanesoctocog alfa is the first factor VIII therapy to be awarded Breakthrough Therapy designation by the FDA
-
May 17, 2022Data to be shared across multiple tumor types, including multiple myeloma, lung cancer and breast cancer
-
May 15, 2022Latest results of the Phase 3 IKEMA trial demonstrate the longest median progression free survival (mPFS) on a proteasome inhibitor backbone in patients who relapsed after a prior therapy, including lenalidomide
-
Apr 21, 2022*Results demonstrate strong, but not universal, correlation between organ clinical responses and clinically meaningful improvements in patient-reported outcomes from a pooled analysis of ROCKstar and KD025-208 clinical trials
-
Apr 14, 2022Results published today in the New England Journal of Medicine showed that treatment with rilzabrutinib resulted in a rapid and durable increase in platelet count in patients with heavily pretreated immune thrombocytopenia (ITP)
-
Apr 4, 2022If approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitis
-
Mar 26, 2022Dupixent significantly reduced itch at 12 weeks, and at 24 weeks nearly three times as many Dupixent patients experienced clinically meaningful reductions in itch and skin lesions
-
Mar 9, 2022Once-weekly efanesoctocog alfa met primary endpoint in phase 3 study, resulting in a clinically meaningful prevention of bleeding episodes (bleed protection)
-
Feb 26, 2022Dupixent 300 mg weekly is the only biologic medicine to show positive, clinically meaningful Phase 3 results in adults and adolescents with eosinophilic esophagitis
-
Feb 26, 2022In this Phase 3 trial, Dupixent added to standard-of-care antihistamines nearly doubled reduction in itch and urticaria activity scores compared to standard-of-care alone at 24 weeks in biologic-naïve patients uncontrolled on antihistamines
-
Feb 24, 2022Preclinical findings showed that tolebrutinib, among the investigational BTK inhibitors tested, had the best combination of brain penetration and potency that reinforces its potential to impact neuroinflammation
-
Feb 24, 2022-Company resubmits Biologics License Application (BLA) for teplizumab for the delay of clinical type 1 diabetes (T1D) in at-risk individuals to the U.S. Food and Drug Administration (FDA)-
-
Feb 10, 2022If approved, Dupixent will be the first biologic medicine available in the U.S. to treat uncontrolled moderate-to-severe atopic dermatitis for these young children
-
Feb 4, 2022Enjaymo is the only approved treatment to decrease the need for red blood cell transfusion due to hemolysis, the destruction of red blood cells, in adults with cold agglutinin disease (CAD)
-
Feb 1, 2022Late-breaking pivotal data show significant disease improvements in eosinophilic esophagitis and also in chronic spontaneous urticaria
-
Jan 27, 2022- Company to Host Conference Call Tomorrow, January 28th at 8:00 AM ET -
-
Jan 20, 2022- PRV-3279 is Designed to Intercept B-Cell Mediated Autoimmune Diseases -
-
Jan 19, 2022Dupixent is the first and only medicine to demonstrate positive Phase 3 results in prurigo nodularis, confirming the potential benefit of targeting IL-4 and IL-13, central drivers of type 2 inflammation, to address itch and skin lesions
-
Dec 20, 2021
-
Dec 13, 2021Dupixent significantly improved skin clearance and reduced overall disease severity and itch in a Pivotal trial that met all primary and secondary endpoints
-
Dec 11, 2021Sarclisa combination therapy is first to demonstrate superiority to standard of care lenalidomide, bortezomib and dexamethasone (RVd) in a Phase 3 trial
-
Dec 8, 2021Dupixent significantly reduced severe asthma attacks and improved lung function and asthma control in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma
-
Nov 30, 2021* Regardless of gender or sexual orientation, employees welcoming a child into their family receive equal amount of paid time off
-
Nov 4, 2021Andrew Drechsler to Retire as Chief Financial Officer in December
-
Oct 26, 2021PRV-101 was well tolerated and elicited high titers of virus-neutralizing antibodies in a dose-dependent fashion in healthy volunteers
-
Oct 25, 2021Dupixent 300 mg weekly significantly improved the ability to swallow and reduced eosinophils in the esophagus compared to placebo, reinforcing positive results from first Phase 3 trial
-
Oct 22, 2021Pivotal trial met primary and all key secondary endpoints
-
Oct 20, 2021Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
-
Oct 7, 2021First study to investigate the safety and immunogenicity of both vaccines when co-administered compared to each vaccine administered separately in adults aged 65 years and older
-
Sep 28, 2021Presentations focused on respiratory syncytial virus, meningococcal disease, and influenza
-
Sep 19, 2021*Phase 3 trial met its primary and key secondary endpoints
-
Sep 13, 2021Data collection completed for PROTECT Pharmacokinetic/Pharmacodynamic (PK/PD) substudy
-
Aug 30, 2021Dupixent rapidly improved symptoms after first dose, improving itch in one week and skin clearance in two weeks
-
Aug 6, 2021Approval is based on positive Phase 3 data demonstrating improvements in key disease burden measures and establishing its safety profile
-
Aug 5, 2021Libtayo combined with chemotherapy increased median overall survival from 13 to 22 months, leading to a 29% reduction in the risk of death
-
Jul 29, 2021Fifth disease that Dupixent has demonstrated positive pivotal results
-
Jul 12, 2021Designation is the first step in a new MHRA initiative to accelerate the development and access to innovative medicines in the UK post-Brexit
-
Jul 6, 2021Previously reported pharmacokinetic (PK) drug product comparability considerations remain outstanding
-
Jul 2, 2021New research from first-in-class marketed and investigational therapies in hemophilia, immune thrombocytopenia and acquired thrombotic thrombocytopenic purpura will be presented
-
Jun 28, 2021* Study also shows more people on Soliqua 100/33 had improved blood sugar control without weight gain and without low blood sugar events (hypoglycemia) in first head-to-head comparison with premixed insulin
-
Jun 28, 2021- Respiratory syncytial virus (RSV) is the leading cause of hospitalization in all infants1,2
-
Jun 17, 2021* $425 million investment in Sanofi's Swiftwater, PA facility expands production of Fluzone® High-Dose Quadrivalent for people 65 and older in the U.S.
-
Jun 11, 2021Phase 3 data from the CADENZA study met the primary composite endpoint with statistical significance; secondary endpoint data were clinically meaningful
-
Jun 4, 2021* Sanofi partnering with the Breast International Group (BIG), the European Organization for Research and Treatment of Cancer (EORTC) and Alliance Foundation Trials (AFT), which are world-leading academic groups delivering practice-changing breast cancer clinical research
-
Jun 1, 2021* This combination vaccine may simplify execution and reduce shots needed to complete CDC's recommended child and adolescent immunization schedule
-
May 27, 2021If approved, teplizumab will be the first disease-modifying therapy in T1D
-
May 27, 2021-- FDA Advisory Committee to Review Biologics License Application for PRV-031 for the Delay of Clinical Type 1 Diabetes --
-
May 19, 2021Early clinical data for investigational oral selective estrogen receptor (SERD), amcenestrant, show potential to become a new endocrine backbone therapy in ER+ HER2- breast cancer
-
May 19, 2021- Amcenestrant, an investigational oral selective estrogen receptor degrader (SERD), achieved an objective response rate of 34% and a clinical benefit rate of 74% in Phase 1 study (AMEERA-1) in combination with palbociclib
-
May 17, 2021- Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma in a randomized Phase 3 trial, with potential to be best-in-class treatment for these patients
-
May 12, 2021Libtayo is the first immunotherapy to demonstrate an improvement in overall survival in advanced cervical cancer, as well as progression-free survival and objective response rate, compared to chemotherapy
-
May 6, 2021Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research* Projects led by collaborating researchers from the two organizations will focus on autoimmune diseases and inflammatory conditions
-
Apr 26, 2021- Sanofi is the only company to leverage its manufacturing capacity and expertise to support three different COVID-19 vaccines to support the global supply of vaccines and help address the pandemic
-
Apr 26, 2021Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization in all infants.1-5
-
Apr 23, 2021Nearly 30 data presentations at AAD and ESPD across clinical and real-world settings, including the impact of Dupixent on disease measures in uncontrolled moderate-to-severe atopic dermatitis
-
Apr 8, 2021- Conference call and webcast to be held today at 5:00 p.m. Eastern Time -
-
Apr 7, 2021Data from the pivotal Phase 3 CARDINAL study demonstrated sutimlimab inhibited C1-activated hemolysis (abnormal destruction of healthy red blood cells) within one week of treatment and had a sustained treatment effect over the course of the study
-
Apr 7, 2021* Launch of a new and more impactful global corporate social responsibility strategy